menu
    • menu
    [{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"SPJ-001","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Sen-Jam Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sen-Jam Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"SJP-002C","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sen-Jam Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sen-Jam Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"Duke University School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Ketotifen Fumarate","moa":"H1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sen-Jam Pharmaceutical \/ Duke University School of Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Sen-Jam Pharmaceutical \/ Duke University School of Medicine"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"KVK.Tech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Ketotifen Fumarate","moa":"H1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sen-Jam Pharmaceutical \/ KVK Tech","highestDevelopmentStatusID":"10","companyTruncated":"Sen-Jam Pharmaceutical \/ KVK Tech"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Naproxen","moa":"COX-1","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Sen-Jam Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sen-Jam Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"KVK.Tech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Ketotifen Fumarate","moa":"H1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sen-Jam Pharmaceutical \/ KVK Tech","highestDevelopmentStatusID":"8","companyTruncated":"Sen-Jam Pharmaceutical \/ KVK Tech"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"KVK.Tech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ketotifen Fumarate","moa":"H1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sen-Jam Pharmaceutical \/ KVK Tech","highestDevelopmentStatusID":"8","companyTruncated":"Sen-Jam Pharmaceutical \/ KVK Tech"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"KVK-Tech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"SJP-100","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sen-Jam Pharmaceutical \/ KVK-Tech","highestDevelopmentStatusID":"4","companyTruncated":"Sen-Jam Pharmaceutical \/ KVK-Tech"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"SJP-002C","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Sen-Jam Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sen-Jam Pharmaceutical \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Sen-Jam Pharmaceutical

    Menu

    Sen-Jam Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sen-Jam Pharmaceutical

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Sen-Jam Pharmaceutical

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SJP-002C

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sen-Jam Pharmaceutical Nears Completion of SJP-002C Trial for Respiratory Infections

                            Details : SJP-002C is a combination of a non-steroidal anti-inflammatory drug and antihistamine, orally available anti-inflammatory a person could obtain for a mild to moderate respiratory tract infections.

                            Brand Name : SJP-002C

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 22, 2024

                            Lead Product(s) : SJP-002C

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sen-Jam Pharmaceutical

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Sen-Jam Pharmaceutical

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SJP-100

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : KVK-Tech

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Sen-Jam Partners To Provide Manufacturing for Anti-Inflammatory Injectable

                            Details : KVK-Tech provides formulation and Manufacturing & Controls for Sen-Jam's first injectable anti-inflammatory therapeutic, SJP-100, which reduces inflammatory protein release from the immune system.

                            Brand Name : SJP-100

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 10, 2024

                            Lead Product(s) : SJP-100

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : KVK-Tech

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sen-Jam Pharmaceutical

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Sen-Jam Pharmaceutical

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ketotifen Fumarate,Indomethacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : KVK.Tech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sen-Jam Pharmaceutical Opens Enrollment for Patients in Their COVID Therapy Phase 2 Clinical Trial in Nepal an...

                            Details : SJP-002C (ketotifen) world most potent, orally available anti-inflammatory a person could obtain for a mild to moderate coronavirus infection, Sen-Jam's investigational therapeutic for treatment of COVID-19, SJP-002C is now actively enrolling patients fo...

                            Brand Name : SJP-002C

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 06, 2022

                            Lead Product(s) : Ketotifen Fumarate,Indomethacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : KVK.Tech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sen-Jam Pharmaceutical

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Sen-Jam Pharmaceutical

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ketotifen Fumarate,Indomethacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : KVK.Tech

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            KVK Tech Announces Phase II Trial of COVID-19 Oral Therapy is Currently Enrolling in Nepal

                            Details : KVK will have exclusive manufacturing and supply rights for the product SJP-002C (Ketotifen) in the US. Sen-Jam will utilize the finished formulation and CMC report to enter licensing deals with contracting manufacturing companies (CMOs) globally.

                            Brand Name : SJP-002C

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 05, 2022

                            Lead Product(s) : Ketotifen Fumarate,Indomethacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : KVK.Tech

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sen-Jam Pharmaceutical

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Sen-Jam Pharmaceutical

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ketotifen Fumarate,Indomethacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : KVK.Tech

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Sen-Jam Pharmaceutical Partners with Specialty Pharmaceutical Manufacturer to Provide Formulation and Chemistr...

                            Details : Sen-Jam Pharmaceutical has entered a development, manufacturing, distribution, and license agreement with KVK-Tech. This is a monumental milestone for the company and great news for their promising oral COVID-19 treatment, SJP-002C.

                            Brand Name : SJP-002C

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 22, 2022

                            Lead Product(s) : Ketotifen Fumarate,Indomethacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : KVK.Tech

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sen-Jam Pharmaceutical

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Sen-Jam Pharmaceutical

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naproxen,Fexofenadine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Alcohol Hangover Treatments and the Classification for Treating Hangovers as a Disease

                            Details : Results from a recent pilot study showed that SJP-001, comprising a combination of naproxen and fexofenadine was significantly more effective in reducing alcohol hangover severity than placebo.

                            Brand Name : SJP-001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 17, 2022

                            Lead Product(s) : Naproxen,Fexofenadine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Sen-Jam Pharmaceutical

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Sen-Jam Pharmaceutical

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ketotifen Fumarate,Indomethacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Duke University School of Medicine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Sen-Jam Pharmaceutical Partners with Leading Academic Medical Centers in Promising Novel Oral COVID-19 Therape...

                            Details : The collaboration received official approval this past Friday from the Nepal Health Research Council and is now commencing Phase II Clinical Trials of SJP-002C, for a novel oral therapy to mitigate the symptoms and hospitalizations associated with COVID-...

                            Brand Name : SJP-002C

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 22, 2022

                            Lead Product(s) : Ketotifen Fumarate,Indomethacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Duke University School of Medicine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Sen-Jam Pharmaceutical

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Sen-Jam Pharmaceutical

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SJP-002C

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sen-Jam Pharmaceutical Planning to Trial Oral COVID Therapy

                            Details : Sen-Jam’s investigational therapeutic for COVID-19, SJP-002C is scheduled to begin a clinical trial in December 2021 under a co-development agreement with Duke-NUS. SJP-002C is a potent anti inflammatory with antiviral capabilities and minimal s...

                            Brand Name : SJP-002C

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 12, 2021

                            Lead Product(s) : SJP-002C

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Sen-Jam Pharmaceutical

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Sen-Jam Pharmaceutical

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SPJ-001

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sen-Jam Pharmaceutical Enters Phase I Clinical Study on Alcohol Hangover Treatment

                            Details : Sen-Jam has an open FDA Investigational New Drug (IND) application to begin a phase I clinical study for SPJ-001 and is in late-stage discussions with a US Licensee for distribution.

                            Brand Name : SPJ-001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 23, 2021

                            Lead Product(s) : SPJ-001

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth